Anti-BCMA CAR-T Cells | 78660-2

Anti-BCMA CAR-T Cells | 78660-2 | Gentaur US, UK & Europe Disrtribition

Category: CAR-T/Cell Line

Application: Positive control for anti-BCMA CAR-T cells Screen inhibitors or activators of anti-BCMA CAR-T cytotoxicity Design and optimize co-culture cytotoxicity assay

Background: B-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and on Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy because of its restricted expression in nonmalignant tissue but almost universal expression on MM cells. So far FDA has approved two BCMA CAR-T therapies for the treatment of multiple myeloma.

Description: The anti-BCMA CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-BCMA CAR Lentivirus (BPS Bioscience #78655). These ready-to-use CAR-T cells express an anti-BCMA CAR consisting of the ScFv of BCMA (clone C11D5.3) linked to a 2^nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (Figure 1). These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays.

Product Type: Cell Line

Shippement Condition: -80°C